A clinical trial involving ganirelix was updated on July 2, 2026. The study, titled "Disentangling the Effects of Daily Stress, Sleep, and Sex Hormones on Accelerated Vascular Aging in Midlife Women," is registered as NCT06745466. It is listed as a Phase 4 trial. Its current status is recruiting. The trial explores factors related to daily stress, sleep, and sex hormones in the context of vascular aging among midlife women. No results have been posted for this trial at this time. The study record can be reviewed on ClinicalTrials.gov under the identifier NCT06745466. As with any actively recruiting trial, details such as design, endpoints, and outcomes may evolve as the study progresses. Readers should refer to the official listing for the most current information regarding eligibility, objectives, and enrollment status. For additional background on ganirelix, including its approved uses and general profile, readers can consult the compound overview.
Ganirelix Featured in Phase 4 Trial on Vascular Aging in Women
See the full ganirelix overview
Source: https://clinicaltrials.gov/study/NCT06745466